Applies to most patients with one or two positive sentinel lymph nodes ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Five-year OS was 94.4% with ALND omission vs 93.4% with completion ALND (HR 0.89), confirming non-inferiority; breast cancer–specific survival was similarly high in both arms. Inclusion of mastectomy ...

SENOMAC at ASCO 2026 shows skipping completion ALND in select breast cancer keeps survival high and cuts lymphedema, boosting ...

Karen underwent a left mastectomy and axillary node clearance in July 2017. Results showed a large (>5cm) but slowly growing hormone sensitive cancer with two affected lymph nodes. Chemotherapy is the ...

A pioneering surgical technique is being hailed as life‑changing for North East women undergoing treatment for breast cancer.

Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the ...

Breast cancer patients receiving treatment at East Lancashire Hospitals NHS Trust (ELHT) will be seen quicker thanks to a new ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

Many people with breast cancer can safely avoid chemotherapy with the use of a gene test, potentially sparing them unnecessary side effects without increasing the risk of the cancer returning, a large ...

New approvals for fam-trastuzumab deruxtecan-nxki establish a potential new standard of care in the neoadjuvant and adjuvant settings for patients with HER2-positive early breast cancer.